Walking on Borrowed Strength

For a century, getting your legs back was a matter of rehabilitation: weeks in a corridor, parallel bars, a hand to steady the step. In January 2026, at the CES show in Las Vegas, the Chinese company RoboCT showed another path. Its GoGo exoskeleton, 2.3 kilos per leg, straps to the hips in seconds and walks alongside whoever wears it, in the street, up the stairs, on the trail. The machine does not heal the gait; it lends it.

The idea is worth pausing on. An exoskeleton replaces no organ and repairs no injury; it adds force where the body lacks it. For someone who struggles to rise from a chair, or who gave up hiking long ago, a share of autonomy comes back, step by step. But a question the promise sidesteps remains: does borrowed strength rebuild autonomy, or does it quietly stand in for what was still there?

From the Hospital Corridor to the Trail

RoboCT does not come from leisure but from the clinic. Its devices first served stroke rehabilitation and support for Parkinson's disease, where every step is retrained under supervision. The GoGo carries that knowledge into ordinary life: four modes, Walk, Stand/Sit, Cadence and Swing, an assist that the onboard intelligence tunes in real time to each person's movement, and a range stated at up to 25 kilometers. The medical object has come down into the street.

At the other end of the market, brands like Hypershell aim straight at consumers. Its most finished model delivers up to 1,000 watts of power, claims some thirty kilometers of range, and sells for around 2,000 dollars. Software learns the wearer's stride and syncs the motor to it. Here there is no patient and no prescription: a hiker who wants to climb higher, for longer, with less effort.

Between these two poles, the same shift is underway. The exoskeleton is leaving the status of a device prescribed, adjusted and monitored, for that of an object you buy and strap on alone. The market, put at more than two billion dollars by 2030, follows that slope, driven above all by the powered models. Assisted strength stops being care and becomes a product.

What Borrowed Strength Returns

For those who need it, the benefit is anything but abstract. An older person who dreaded the stairs climbs them again; a one-kilometer walk stops costing the whole day. The assist does not make you faster, it makes things possible: it moves the line between giving up and going. That is exactly what mindshot looks for in such machines, time and ease handed back to a life that fatigue had narrowed.

The gain lies in the fineness of the tuning. The motor does not push blindly; it reads the stride, matches its force to the terrain, holds back a movement about to go wrong. Well set, the exoskeleton disappears: it does not carry in the body's place, it completes the effort the body no longer makes alone. For impaired mobility, that is the difference between going out and staying shut in.

This is autonomy in its first sense: not a technical feat, but leaving home without counting every step, without needing an arm to sit down, without giving up in advance. Twenty-five kilometers of range is not a spec-sheet figure; it is a day outdoors that one no longer dared to picture.

The Leg You No Longer Exercise

The trade-off begins with the battery. The assist lasts as long as the charge; beyond it, the motor stops and the leg is on its own, sometimes wearier for having leaned on it all day. The machine that grants autonomy creates, in the same motion, a leash: you have to remember to charge it, strap it on, carry it. Independence won is paid for with a new dependence, quieter than the old one.

Deeper still, there is the muscle. A leg the motor relieves works less. In rehab, the assist is scaffolding: it is withdrawn as strength returns, under a clinician's eye. In consumer use, no one weans anyone. The risk is well known, and it should be named: the device meant to preserve mobility can, by stealth, make itself necessary. For a real deficit, the gain stays clear; for mere tiredness, the crutch could weaken what it claims to support.

Who Owns the Walk

Then comes the price. Two thousand dollars for a finished model is autonomy you buy, and that the most fragile, the ones who would gain most, will not buy. Volumes stay slim, a few dozen units a month for the high end. The promise of mobility returned to all meets, for now, the reality of an object reserved for those who can afford it.

And there is the data. To tune its force, the exoskeleton learns the stride, which amounts to recording an intimate signature of the body, its cadence, its weaknesses, its drift from one day to the next. Who holds that imprint, and to what end? To entrust your walk to a machine is also to entrust it with a faithful account of your own aging.

The exoskeleton is one of the rare technologies whose promise is literal: it gives back movement, and so a measure of life. But autonomy is not only the power to move; it is not depending on a thing in order to do so. The true measure will not be how many kilometers the battery offers you, but this, on the day you take it off: do you still walk?